NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BioNTech SE (BNTX) Stock Analysis

BioNTech SE (BNTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BNTX

$91.29

+$0.12 (+0.13%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BNTX with… →

BNTX Key Statistics

As of Oct 21, 2026
Trading
Open
$91.25
Previous Close
$91.17
Day's Range
91.02–92.35
52-Week Range
79.52–124.00
Volume
1.11M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.25
Valuation
Market Cap
$22.66B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.05
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.55
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.80
Financials (FY)
Revenue (FY)
$2.87B+4.32%
Net Income (FY)
−$1.14B
Profit marginThe share of revenue left as profit after all costs and taxes.
−63.64%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
251.20M
1-Year Return
−14.59%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BNTX closed at $91.29, −14.59% over 1 year.

BioNTech SE (BNTX) has a market capitalization of $22.66B.

In fiscal 2025, BNTX reported revenue of $2.87B.

BNTX Stock Return by Calendar Year

BioNTech SE (BNTX) return since Oct 2019: what $10,000 became

1 year
$10,000 $8,541
−14.59%
5 years
$10,000 $3,230
−67.70%
Since Oct 2019
$10,000 $64,957
+549.57%

If you had invested $10,000 in BioNTech SE (BNTX) at the close on October 10, 2019, the earliest close on record here, it would have been worth $64,957 at the close on October 21, 2026: +549.57% in total, +30.49% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.11%
2025−16.45%
2024+7.97%
2023−29.74%
2022−40.96%
2021+216.24%
2020+140.61%
2019 (partial year)+137.92%

As of October 21, 2026.

BNTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.87B−$1.14B−39.6%
2024$2.75B−$665.30M−24.2%
2023$3.82B$930.30M24.4%
2022$17.31B$9.43B54.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.87B$2.23B−$640.70M−$1.14B−39.6%
2024$2.75B$2.21B−$709.40M−$665.30M−24.2%
2023$3.82B$3.22B$875.60M$930.30M24.4%
2022$17.31B$14.32B$12.30B$9.43B54.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BNTX Valuation vs Biotechnology Median

Median of 608 stocks
MetricBNTXBiotechnology medianvs median
P/S ratio8.5513.3036% below
Profit margin−63.64%−38.31%25.3 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioNTech SE (BNTX) carries a market capitalisation of $22.66B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 7,807.

The 52-week range on file runs from $79.52 to $124.00. BNTX last closed at $91.29 on October 21, 2026. That is +$0.12 (+0.13%) against the previous close. The latest close sits 14.8% above that 52-week low.

Financial Health

In fiscal 2025, BioNTech SE reported revenue of $2.87B. That is +4.32% against the prior fiscal year, when revenue was $2.75B. The same year closed with a net loss of $1.14B. Profit margin runs at −63.64%. That is 25.3 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −7.8.

Across the 4 fiscal years on file, revenue moves from $17.31B in 2022 to $2.87B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.05. The price-to-sales ratio is 8.55. On price-to-sales that is 35.7% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.25. Annualized volatility over the trailing 7 years is 74.88%. Over the trailing twelve months the total return is −14.59%. Across 5 years the annualized return works out at −20.23%.

Growth & Income

The latest dividend on file for BNTX dates from 2022.

Across the complete calendar years on file, 2021 returned +216.24% and 2022 returned −40.96%. Of the 6 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −4.11% year to date.

Peer Comparison

BioNTech SE (BNTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioNTech SE BNTX $22.66B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BioNTech SE has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Visit website →